← Back to Search

Surveillance Strategies for Lung Cancer (WTS Trial)

N/A
Waitlist Available
Led By Michael K Gould, MD, MS
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare two different protocols for follow-up imaging of small pulmonary nodules discovered on chest CT scans.

Who is the study for?
This trial is for adults over 35 years old who have small lung nodules, possibly indicating early-stage lung cancer, and would normally be monitored with CT scans. Pregnant women or those under 35, or anyone diagnosed with a type of cancer (other than non-melanoma skin cancer) in the last five years cannot participate.
What is being tested?
The 'Watch the Spot Trial' is comparing two different schedules for follow-up CT scans to monitor small lung nodules. One group will have less frequent check-ups while the other will have more frequent surveillance to see which strategy is better.
What are the potential side effects?
Since this trial involves monitoring strategies rather than medication, there are no direct side effects from interventions. However, there may be indirect effects such as anxiety from more frequent testing or potential delays in diagnosis with less frequent testing.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Malignant Neoplasms
Secondary study objectives
Anxiety, measured with the State Anxiety Inventory, 6-item
Fetal Distress
Exposure to ionizing radiation, using the computed tomography dose index (CTDIvol), measured in mGy (milliGray)
+6 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: More Frequent CT SurveillanceActive Control1 Intervention
Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
Group II: Less Frequent CT SurveillanceActive Control1 Intervention
Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor
556 Previous Clinical Trials
27,697,035 Total Patients Enrolled
Patient-Centered Outcomes Research InstituteOTHER
580 Previous Clinical Trials
27,070,059 Total Patients Enrolled
University of California, DavisOTHER
946 Previous Clinical Trials
4,720,930 Total Patients Enrolled
University of California, San FranciscoOTHER
2,593 Previous Clinical Trials
14,852,750 Total Patients Enrolled
Michael K Gould, MD, MSPrincipal InvestigatorKaiser Permanente School of Medicin

Media Library

Less Frequent Surveillance Strategy Clinical Trial Eligibility Overview. Trial Name: NCT02623712 — N/A
Solitary Pulmonary Nodule Research Study Groups: More Frequent CT Surveillance, Less Frequent CT Surveillance
Solitary Pulmonary Nodule Clinical Trial 2023: Less Frequent Surveillance Strategy Highlights & Side Effects. Trial Name: NCT02623712 — N/A
Less Frequent Surveillance Strategy 2023 Treatment Timeline for Medical Study. Trial Name: NCT02623712 — N/A
~3985 spots leftby Jan 2026